Skip to main content
OpenTrials
Completed

NCT Number: NCT00472472

Paclitaxel Coated Balloon Catheter for Prevention of Restenosis in Femoropopliteal Arteries

The PACCOCATH FEM study is a randomized, double-blinded German multicenter trial on the efficacy and tolerance of a paclitaxel coated balloon catheter in prevention of restenosis after femoropopliteal angioplasty.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year–95 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 1 / Phase 2

Primary location

Klinik für Strahlenheilkunde, Charité Campus Virchow Klinikum, Berlin, Germany

Loading trial locations.

About this study

Background: Treatment of patients with peripheral arterial disease (PAD) in the femoropopliteal arteries by percutaneous intervention is still limited by high rates of restenosis. The aim of the present study is to evaluate the efficacy and safety of a novel method of short time local drug delivery based on a paclitaxel-coated balloon in femoropopliteal arteries.

Methods and results: The double-blind and randomized study enrolled n=79 patients with occlusion or stenosis of femoropopliteal arteries. Inclusion criteria were clinical Rutherford stage 1-5, occlusion or hemodynamic relevant stenosis (≥ 70 % diameter) of femoropopliteal arteries and successful guiding wire recanalization. The primary endpoint was the late lumen loss after 6 months follow-up as seen in angiography. Secondary endpoints included the rate of restenosis (a binary variable), change of ankle brachial index (ABI), rutherford class and major adverse events.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Rutherford stage 1, 2, 3, 4 oder 5
  • Occlusion or Stenosis of Superficial femoral and/or popliteal artery
  • Successful guide wire passage of the lesion
  • Patient suitable of vascular surgery in case of complication
  • Written consent
  • Patient is willing to take part in follow up examinations within the study

Exclusion criteria

  • Acute ischemia
  • Distal run off less than one vessel
  • Pregnancy
  • Hyperthyroidism
  • Thrombocytes <100.000/mm3 or >700.000/mm3, Leucocytes <3.000/mm3
  • Life expectancy less than two years
  • Patients not willing to enter the study

Treatment and study plan

paclitaxel coated balloon catheter (device with drug)

Device

PTA vs Paccocath

Primary outcomes

  1. angiographic late lumen loss

    Time frame: 6 months

Secondary outcomes

  1. binary restenosis rate; major adverse events

    Time frame: 18 months

Sponsors and collaborators

Lead sponsor

University Hospital, Saarland

Other

Registry information

Official study title

Paclitaxel Coated Balloon Catheter for Inhibition of Restenosis in Femoropopliteal Arteries (PACCOCATH - FEM I)

Acronym: PACCOCATH_F

Important dates

Study start
2004
Primary completion
2007
Study completion
2007
First posted
May 11, 2007
Registry last updated
Jun 30, 2010

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.